Quotes 5-day view Delayed Nasdaq
06/29/2022
06/30/2022
07/01/2022
07/05/2022
07/06/2022
Date
51.85(c)
51.43(c)
57.15(c)
64.29(c)
63.54
Last
4 113 231
3 556 907
6 423 652
7 175 284
5 869 935
Volume
+1.55%
-0.81%
+11.12%
+12.49%
-1.17%
Change
Estimated financial data (e) (USD)
Sales 2022
4 384 M
-
-
Net income 2022
2 019 M
-
-
Net cash position 2022
2 508 M
-
-
P/E ratio 2022
2,57x
Yield 2022
-
Sales 2023
3 086 M
-
-
Net income 2023
916 M
-
-
Net cash position 2023
3 354 M
-
-
P/E ratio 2023
6,09x
Yield 2023
-
Capitalization
5 023 M
5 023 M
-
EV / Sales 2022
0,57x
EV / Sales 2023
0,54x
Nbr of Employees
1 541
Free-Float
98,8%
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address...
All news about NOVAVAX, INC.
News in other languages on NOVAVAX, INC.
Analyst Recommendations on NOVAVAX, INC.
COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends NOVAVAX, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
64,29 $
Average target price
149,17 $
Spread / Average Target
132%
Please enable JavaScript in your browser's settings to use dynamic charts.